What are the indications, dosing guidelines, contraindications, and monitoring recommendations for Latuda (lurasidone)?

Latuda (Lurasidone): Clinical Guide

Indications

Latuda is FDA-approved for schizophrenia in adults and adolescents (13-17 years), and for bipolar I depression in adults and pediatric patients (10-17 years) as monotherapy or adjunctive therapy with lithium or valproate. 1

Specifically:

• Schizophrenia: Adults and adolescents 13-17 years
• Bipolar I Depression: Adults and pediatric patients 10-17 years (monotherapy)
• Bipolar I Depression: Adults only (adjunctive with lithium or valproate)

Critical Dosing Requirements

Must Take With Food

Latuda MUST be taken with at least 350 calories of food - this is non-negotiable as food substantially increases absorption and bioavailability. 1, 2 Without adequate food intake, patients will be significantly underdosed.

Standard Dosing by Indication

Schizophrenia - Adults:

• Starting dose: 40 mg daily
• Therapeutic range: 40-160 mg daily
• No titration required 1

Schizophrenia - Adolescents (13-17 years):

• Starting dose: 40 mg daily
• Therapeutic range: 40-80 mg daily 1

Bipolar Depression - Adults:

• Starting dose: 20 mg daily
• Therapeutic range: 20-120 mg daily 1

Bipolar Depression - Pediatric (10-17 years):

• Starting dose: 20 mg daily
• Therapeutic range: 20-80 mg daily 1

Dose Adjustments for Special Populations

Moderate to Severe Renal Impairment:

• Starting dose: 20 mg daily
• Maximum dose: 80 mg daily 1

Moderate Hepatic Impairment:

• Starting dose: 20 mg daily
• Maximum dose: 80 mg daily 1

Severe Hepatic Impairment:

• Starting dose: 20 mg daily
• Maximum dose: 40 mg daily 1

Elderly Patients: Recent expert consensus suggests 20-80 mg daily with careful monitoring 3

Contraindications

Latuda is absolutely contraindicated with:

1. Strong CYP3A4 inhibitors (e.g., ketoconazole) - causes 9-fold increase in lurasidone exposure 1, 4
2. Strong CYP3A4 inducers (e.g., rifampin) - reduces lurasidone levels to one-fifth 1, 4
3. Known hypersensitivity to lurasidone or formulation components 1

Drug Interactions Requiring Dose Adjustment

Moderate CYP3A4 Inhibitors (e.g., diltiazem):

• Reduce Latuda dose to half the original level
• Starting dose: 20 mg daily
• Maximum dose: 80 mg daily
• These cause a 2-fold increase in lurasidone exposure 1, 4

Moderate CYP3A4 Inducers:

• May need to increase Latuda dose 1

No dose adjustment needed for:

• Lithium, valproate, digoxin, oral contraceptives, or midazolam 4

Important caveat: Valproic acid co-administration may reduce lurasidone levels by approximately 55% based on recent Chinese population data, though FDA labeling does not require dose adjustment 5

Monitoring Recommendations

Baseline Assessment

• Complete blood count (if history of leukopenia/neutropenia or low WBC) 1
• Metabolic panel: fasting glucose, lipids, weight, BMI 1
• Blood pressure and heart rate (orthostatic vital signs) 1
• Prolactin level (if clinically indicated) 1

Ongoing Monitoring

• Weight and metabolic parameters: Regular monitoring for hyperglycemia, diabetes, dyslipidemia, and weight gain 1
• Movement disorders: Assess for akathisia, extrapyramidal symptoms, and tardive dyskinesia at each visit 1
• CBC: Continue monitoring if baseline abnormalities; discontinue if clinically significant WBC decline without other cause 1
• Cardiovascular: Monitor blood pressure and heart rate, especially in patients with cardiovascular disease 1
• Suicidality: Close monitoring in pediatric and young adult patients for clinical worsening and suicidal thoughts 1

Special Monitoring Considerations

For bipolar patients: Monitor closely for manic switch, particularly during the first 1-2 weeks of treatment. One case report documented acute mania developing within 1-2 weeks of lurasidone initiation despite concurrent mood stabilizer 6

For elderly patients and those on valproate: Consider therapeutic drug monitoring, as these populations show significantly altered drug levels 5

Key Warnings

Black Box Warnings

1. Increased mortality in elderly patients with dementia-related psychosis - Latuda is NOT approved for this population 1
2. Suicidal thoughts and behaviors in pediatric and young adult patients 1

Major Safety Concerns

• Neuroleptic malignant syndrome: Discontinue immediately if suspected 1
• Tardive dyskinesia: Consider discontinuation if clinically appropriate 1
• Cerebrovascular events: Increased risk in elderly with dementia 1
• Orthostatic hypotension and syncope: Particularly in patients with cardiovascular disease 1
• Hyperprolactinemia: Prolactin elevations may occur 1

Common Adverse Effects

Adults with schizophrenia (≥5% and twice placebo rate):

• Somnolence, akathisia, extrapyramidal symptoms, nausea 1

Adolescents with schizophrenia:

• Somnolence, nausea, akathisia, extrapyramidal symptoms, rhinitis (80 mg only), vomiting 1

Adults with bipolar depression:

• Akathisia, extrapyramidal symptoms, somnolence 1

Pediatric patients with bipolar depression:

• Nausea, weight increase, insomnia 1

Metabolic Profile Advantage

Latuda demonstrates a highly favorable metabolic profile compared to many other atypical antipsychotics, with minimal weight gain and no clinically meaningful alterations in glucose, lipids, or QTc interval. 7, 8, 2 This makes it particularly appropriate for patients who are overweight or have diabetes, dyslipidemia, or cardiovascular comorbidities.

Pregnancy Considerations

Exercise caution when prescribing during pregnancy, particularly in the first trimester. Third-trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. 1, 3